Trump Signs Order to Accelerate Psychedelic Research, Allocates $50 Million for Ibogaine Studies

**TL;DR** The executive order earmarks $50 million for ibogaine research on PTSD and addiction, tells the FDA to streamline psychedelic drug approvals, and expands Right‑to‑Try access for severely ill patients.

**Context** Nearly one in five U.S. adults experiences mental illness each year, and veterans face disproportionately high rates of PTSD. Psychedelic compounds such as ibogaine have shown early promise in reducing cravings and withdrawal symptoms, but they remain experimental and lack FDA approval. Advocacy groups have urged faster research pathways to address gaps in existing therapies.

**Key Facts** Trump stated that experimental psychedelic treatments have demonstrated life‑changing potential for people with severe mental illness and depression, especially veterans. The administration announced $50 million in federal funding to support state‑level research on ibogaine for PTSD and addiction treatment. The order instructs the FDA to streamline approval processes for psychedelic‑based treatments, aiming to shorten timelines and reduce regulatory barriers. It also expands the Right‑to‑Try law, allowing severely ill patients to access experimental therapies earlier while studies continue. Robert F. Kennedy Jr. endorsed the initiative, saying it will remove legal impediments that block proper study of these medicines.

**What It Means** The $50 million will likely fund pilot and cohort trials that examine ibogaine’s safety and efficacy in veteran populations; early data from small controlled studies suggest up to a 60‑70% improvement in PTSD symptoms, though those findings are correlational and do not prove causation. By directing the FDA to accelerate reviews, the order could shorten the typical multi‑year approval timeline for psychedelic drugs, potentially bringing new options to market sooner if safety profiles are confirmed. Expanding Right‑to‑Try access may give patients with limited alternatives a legal route to try ibogaine under medical supervision, increasing real‑world data collection.

Watch for upcoming FDA guidance on psychedelic drug applications and the first results from federally funded ibogaine trials expected within the next two years.